Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00111943 · ClinicalTrials.gov registry record · Phase 2
Safety and Acceptability of a Vaginal Microbicide
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT00111943 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 200 participants.
The verdict
NCT00111943, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and acceptability of a vaginal microbicide in HIV uninfected sexually active women. Study hypothesis: The vaginal microbicide 1% tenofovir will be safe and well tolerated in HIV uninfected women who are in good general health.
Interventions
- DRUG 1% tenofovir gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00111943
The ClinicalTrials.gov registry entry for NCT00111943 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 1% tenofovir gel is the first listed.
NCT00111943 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00111943 about?
NCT00111943 is a clinical study titled "Safety and Acceptability of a Vaginal Microbicide". The purpose of this study is to determine the safety and acceptability of a vaginal microbicide in HIV uninfected sexually active women. Study hypothesis: The vaginal microbicide 1% tenofovir will be safe and well tolerated in HIV uninfected women who are in good general health.
What is the current status of trial NCT00111943?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00111943?
The interventions under investigation include: 1% tenofovir gel (DRUG).
Who is sponsoring clinical trial NCT00111943?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.